β5 integrin is the major contributor to the αv integrin-mediated blockade of HIV-1 replication

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 464-470

  Ballana, Ester ^a   Pauls, Eduardo ^a   Clotet, Bonaventura ^a   Perron Sierra, Françoise ^b   Tucker, Gordon C ^b   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA1 INTEGRIN; BETA5 INTEGRIN; BETA6 INTEGRIN; CD51 ANTIGEN; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PROTEIN SUBUNIT; SMALL INTERFERING RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL ADHESION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENZYME SUBSTRATE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL DIFFERENTIATION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV-1; HUMANS; INTEGRIN BETA CHAINS; MACROPHAGES; MONOCYTES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS; RECEPTORS, VITRONECTIN; VIRUS REPLICATION;

EID: 79251535284     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002693     Document Type: Article

References (40)

1. Meltzer, M. S., D. R. Skillman, P. J. Gomatos, D. C. Kalter, and H. E. Gendelman. 1990. Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu. Rev. Immunol. 8: 169-194.
2. Dahl, V., L. Josefsson, and S. Palmer. 2010. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res. 85: 286-294.
3. Bergamaschi, A., and G. Pancino. 2010. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7: 31.
4. De Nichilo, M. O., and G. F. Burns. 1993. Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proc. Natl. Acad. Sci. USA 90: 2517-2521.
5. Shi, C., and D. I. Simon. 2006. Integrin signals, transcription factors, and monocyte differentiation. Trends Cardiovasc. Med. 16: 146-152.
6. Lafrenie, R. M., S. F. Lee, I. K. Hewlett, K. M. Yamada, and S. Dhawan. 2002. Involvement of integrin alphavbeta3 in the pathogenesis of human immunode-ficiency virus type 1 infection in monocytes. Virology 297: 31-38.
7. Hynes, R. O. 1987. Integrins: a family of cell surface receptors. Cell 48: 549-554.
8. Stewart, P. L., and G. R. Nemerow. 2007. Cell integrins: commonly used receptors for diverse viral pathogens. Trends Microbiol. 15: 500-507.
9. Arthos, J., C. Cicala, E. Martinelli, K. Macleod, D. Van Ryk, D. Wei, Z. Xiao, T. D. Veenstra, T. P. Conrad, R. A. Lempicki, et al. 2008. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9: 301-309.
10. Ballana, E., E. Pauls, J. Senserrich, B. Clotet, F. Perron-Sierra, G. C. Tucker, and J. A. Esté. 2009. Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood 113: 1278-1286.
11. Bosch, B., I. Clotet-Codina, J. Blanco, E. Pauls, G. Coma, S. Cedeño, F. Mitjans, A. Llano, M. Bofill, B. Clotet, et al. 2006. Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Res. 69: 173-180.
12. Takada, Y., X. Ye, and S. Simon. 2007. The integrins. Genome Biol. 8: 215.
13. Perron-Sierra, F., D. Saint Dizier, M. Bertrand, A. Genton, G. C. Tucker, and P. Casara. 2002. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists. Bioorg. Med. Chem. Lett. 12: 3291-3296.
14. Burbridge, M. F., V. Venot, P. J. Casara, F. Perron-Sierra, J. A. Hickman, and G. C. Tucker. 2003. Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist. Mol. Pharmacol. 63: 1281-1288.
15. Reynolds, A. R., I. R. Hart, A. R. Watson, J. C. Welti, R. G. Silva, S. D. Robinson, G. Da Violante, M. Gourlaouen, M. Salih, M. C. Jones, et al. 2009. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15: 392-400.
16. Armand-Ugón, M., G. Moncunill, E. Gonzalez, M. Mena, E. Ballana, B. Clotet, and J. A. Esté. 2010. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J. Antimicrob. Chemother. 65: 417-424.
17. Mukhopadhyay, N. K., D. Gilchrist, G. J. Gordon, C. J. Chen, R. Bueno, M. L. Lu, R. Salgia, D. J. Sugarbaker, and M. T. Jaklitsch. 2004. Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. Ann. Thorac. Surg. 78: 450-457.
18. Blaschke, F., P. Stawowy, S. Goetze, O. Hintz, M. Gräfe, U. Kintscher, E. Fleck, and K. Graf. 2002. Hypoxia activates beta(1)-integrin via ERK 1/2 and p38 MAP kinase in human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 296: 890-896.
19. Helfrich, M. H., S. A. Nesbitt, and M. A. Horton. 1992. Integrins on rat osteoclasts: characterization of two monoclonal antibodies (F4 and F11) to rat beta 3. J. Bone Miner. Res. 7: 345-351.
20. Onoue, N., J. Nawata, T. Tada, D. Zhulanqiqige, H. Wang, K. Sugimura, Y. Fukumoto, K. Shirato, and H. Shimokawa. 2008. Increased static pressure promotes migration of vascular smooth muscle cells: involvement of the Rhokinase pathway. J. Cardiovasc. Pharmacol. 51: 55-61.
21. Lin, K. T., S. H. Yeh, D. S. Chen, P. J. Chen, and Y. S. Jou. 2005. Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J. Biomed. Sci. 12: 803-813.
22. Cambier, S., S. Gline, D. Mu, R. Collins, J. Araya, G. Dolganov, S. Einheber, N. Boudreau, and S. L. Nishimura. 2005. Integrin alpha(v)beta8- mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am. J. Pathol. 166: 1883-1894.
23. Ballana, E., J. Senserrich, E. Pauls, R. Faner, J. M. Mercader, F. Uyttebroeck, E. Palou, M. P. Mena, E. Grau, B. Clotet, et al. 2010. ZNRD1 (zinc ribbon domain-containing 1) is a host cellular factor that influences HIV-1 replication and disease progression. Clin. Infect. Dis. 50: 1022-1032.
24. Pauls, E., E. Ballana, G. Moncunill, M. Bofill, B. Clotet, C. Ramo-Tello, and J. A. Esté. 2009. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS 23: 266-268.
25. Moncunill, G., M. Armand-Ugón, E. Pauls, B. Clotet, and J. A. Esté. 2008. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 22: 23-31.
26. González-Ortega, E., M. P. Mena, M. Permanyer, E. Ballana, B. Clotet, and J. A. Esté. 2010. ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation. Antimicrob. Agents Chemother. 54: 4487-4492.
27. Cassol, E., M. Alfano, P. Biswas, and G. Poli. 2006. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J. Leukoc. Biol. 80: 1018-1030.
28. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233: 215-219.
29. Dhawan, S., L. A. Toro, B. E. Jones, and M. S. Meltzer. 1992. Interactions between HIV-infected monocytes and the extracellular matrix: HIV-infected monocytes secrete neutral metalloproteases that degrade basement membrane protein matrices. J. Leukoc. Biol. 52: 244-248.
30. Griffin, G. E., K. Leung, T. M. Folks, S. Kunkel, and G. J. Nabel. 1989. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 339: 70-73.
31. Shattock, R. J., J. S. Friedland, and G. E. Griffin. 1993. Release of human immunodeficiency virus by THP-1 cells and human macrophages is regulated by cellular adherence and activation. J. Virol. 67: 3569-3575.
32. Alfano, M., S. A. Mariani, C. Elia, R. Pardi, F. Blasi, and G. Poli. 2009. Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. Blood 113: 1699-1709.
33. Lima, R. G., J. Van Weyenbergh, E. M. Saraiva, M. Barral-Netto, B. Galvão-Castro, and D. C. Bou-Habib. 2002. The replication of human immunodeficiency virus type 1 in macrophages is enhanced after phagocytosis of apoptotic cells. J. Infect. Dis. 185: 1561-1566.
34. Cicala, C., E. Martinelli, J. P. McNally, D. J. Goode, R. Gopaul, J. Hiatt, K. Jelicic, S. Kottilil, K. Macleod, A. O'Shea, et al. 2009. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. USA 106: 20877-20882.
35. Hodivala-Dilke, K. M., K. P. McHugh, D. A. Tsakiris, H. Rayburn, D. Crowley, M. Ullman-Culleré, F. P. Ross, B. S. Coller, S. Teitelbaum, and R. O. Hynes. 1999. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103: 229-238.
36. Huang, X., M. Griffiths, J. Wu, R. V. Farese, Jr., and D. Sheppard. 2000. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol. Cell. Biol. 20: 755-759.
37. Bader, B. L., H. Rayburn, D. Crowley, and R. O. Hynes. 1998. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95: 507-519.
38. Chen, Q., M. S. Kinch, T. H. Lin, K. Burridge, and R. L. Juliano. 1994. Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J. Biol. Chem. 269: 26602-26605.
39. Wahl, S. M., T. Greenwell-Wild, and N. Vázquez. 2006. HIV accomplices and adversaries in macrophage infection. J. Leukoc. Biol. 80: 973-983.
40. Esté, J. A., and T. Cihlar. 2010. Current challenges in antiretoviral research and treatment. Antiviral Res. 85: 25-33.